CervoMed completes reverse merger, dosed first patient in Phase 2b DLB trial, Q3 cash $10.4M

CervoMed Inc.

First patient dosed in Phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB).
Completed reverse merger; now publicly traded on Nasdaq under ticker CRVO.
Cash and equivalents $10.4M as of Sep 30, 2023; expects cash runway through end of 2024.
Net income of $2.2M in Q3 2023 vs net loss of $0.9M in Q3 2022, driven by noncash gain from convertible notes conversion.
Topline primary efficacy data from RewinD-LB study expected in second half of 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

CervoMed Inc. reported financial results for Third Quarter 2023.

Period: Third Quarter 2023
Result: reported results

Exact text from the filing

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed reverse merger; company now publicly traded on Nasdaq ( “ CRVO ” ) CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available BOSTON, MA – November 13, 2023 – CervoMed Inc. (NASDAQ: CRVO) , a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights.

View on SEC.gov

Browse all earnings releases →

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-031609

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.